Comparative Pharmacology
Head-to-head clinical analysis: METHADOSE versus OXYCODONE AND ACETAMINOPHEN.
Head-to-head clinical analysis: METHADOSE versus OXYCODONE AND ACETAMINOPHEN.
METHADOSE vs OXYCODONE AND ACETAMINOPHEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Oxycodone is a full mu-opioid receptor agonist, producing analgesia via activation of descending inhibitory pathways, while acetaminophen is a centrally acting analgesic and antipyretic, likely through inhibition of cyclooxygenase (COX) in the CNS and modulation of serotonergic pathways.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
Oral: 5-10 mg oxycodone (with 325-650 mg acetaminophen) every 4-6 hours as needed; maximum oxycodone 60 mg/day (for immediate-release) or acetaminophen 4000 mg/day. Titrate to pain control.
None Documented
None Documented
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Oxycodone: 3-5 hours (immediate-release), 4.5-8 hours (extended-release). Acetaminophen: 1.5-3 hours. Clinical context: Half-life may be prolonged in hepatic impairment, elderly, and renal failure.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Oxycodone: renal (primarily as noroxycodone, oxymorphone, and conjugated metabolites; <10% unchanged). Acetaminophen: renal (85-90% as sulfate and glucuronide conjugates; 2-4% unchanged; 8-10% as cysteine and mercapturate conjugates). Biliary/fecal excretion: minor (<5% for both).
Category C
Category D/X
Opioid Agonist
Opioid Agonist